FDA (Food and Drug Administration) Drug Approval Process Training Course: Practical Insights into FDA Requirements and Up to Date Developments (ONLINE EVENT: February 24-25, 2025)
January 30, 2025 07:54 ET
|
Research and Markets
Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
Orphan Drugs Strategic Business Report 2024-2030: Biologics, Oncology & Hospital Pharmacies - The Pulsating Segments of Global Market
January 22, 2025 05:51 ET
|
Research and Markets
Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) -- The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Orphan Drugs was...
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
December 03, 2024 06:00 ET
|
Priothera
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Mocravimod is the only S1P receptor...
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND)
November 21, 2024 06:08 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting
November 14, 2024 16:45 ET
|
Osteal Therapeutics
DALLAS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
MDA Kickstart Program Receives FDA Rare Pediatric Disease Designation and Orphan Drug Designation for Congenital Myasthenic Syndrome
October 24, 2024 12:50 ET
|
Muscular Dystrophy Association
New York, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) proudly announces that its groundbreaking MDA Kickstart program has received both an FDA Rare Pediatric Disease...
Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting
October 15, 2024 11:48 ET
|
Trethera Corporation
LOS ANGELES, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development
September 09, 2024 09:00 ET
|
Muscular Dystrophy Association
New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
August 05, 2024 12:28 ET
|
Osteal Therapeutics
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
July 24, 2024 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...